# Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas

> **NCT00948688** · PHASE1,PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer
- Adenocarcinoma of the Pancreas

## Interventions

- **RADIATION:** Radiation therapy
- **DRUG:** 5-FU
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00948688
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2012-06
- **Final completion:** 2013-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Funding was withdrawn after only 10 participants were enrolled
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948688, "Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00948688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*